Back
“Ionis gets hit harder than AstraZeneca by the Wainua heart drug flop, with shares falling 12% premarket. As the drug's originator, Ionis loses what was a cornerstone cardiovascular pipeline asset in a $15 billion-plus disease market.”
Source
Matthew HerperX“AstraZeneca, Ionis report major trial failure wi…”span
“Ionis shares, meanwhile, were down 12% in premarket hours.”
Performance
Entry$68.00
Current$65.44
Since call+3.76%
Confidence72%
How this was scored
Entry$68.00Jul 9, 2026 · 11:32 UTC · paste.trade
Current$65.44Jul 9, 2026 · 15:42 UTC · Finnhub
Horizonnot specifiedparsed as default-30d
Verdict bandWIN ≥ +2% · LOSS ≤ −2%
Prices are point-in-time snapshots from the named provider. The verdict compares the return since entry against the band above.